BetterLife Pharma Inc. (BETR.CN)
| Previous Close | 0.1000 |
| Open | 0.0000 |
| Bid | 0.1000 x N/A |
| Ask | 0.1100 x N/A |
| Day's Range | 0.0000 - 0.0000 |
| 52 Week Range | |
| Volume | |
| Avg. Volume | 103,224 |
| Market Cap | 11.582M |
| Beta (5Y Monthly) | 1.35 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0200 |
| Earnings Date | May 28, 2024 - Jun 01, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Newsfile
BetterLife Pharma Inc. to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
Vancouver, British Columbia--(Newsfile Corp. - April 15, 2024) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, will be participating in the 2024 Bloom Burton & Co. Healthcare Investor Conference, which will take place on April 16 and 17 at the Metro Toronto Convention Centre. Dates:Tuesday April 16, 2024-Wednesday April 17, 2024Time:8:30 AM-5:00 PM ETLocation: Metro
GlobeNewswireBetterLife To Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
VANCOUVER, British Columbia, April 11, 2024 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, is pleased to announce that Dr. Ahmad Doroudian, Chief Executive Officer, and Dr. Hooshmand Sheshbaradaran, Chief Operating Officer, will present at the upcoming Bloom Burton Healthcare Investor Conference on Tuesda
- GlobeNewswire
BetterLife Announces Closing of $1.168 Million Convertible Debentures to Further Advance IND-enabling Studies of its Non-hallucinogenic LSD-based Drug Candidate BETR-001
VANCOUVER, British Columbia, April 03, 2024 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, is pleased to announce the closing of $1.168 million of convertible debentures to further advance the development of its lead compound, BETR-001. BETR-001 is BetterLife’s proprietary 2-bromo-LSD, a non-hallucinogeni
